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study question: Does triiodothyronine (T3) regulate the secretion of angiogenic growth factors and cytokines by human decidual cells
isolated from early pregnancy?
summary answer: T3 modulates the secretion of speciﬁc angiogenic growth factors and cytokines, with different regulatory patterns
observed amongst various isolated subpopulations of human decidual cells and with a distinct change between the ﬁrst and second trimesters
of pregnancy.
what is known already: Maternal thyroid dysfunction during early pregnancy is associated with complications of malplacentation
including miscarriage and pre-eclampsia. T3 regulates the proliferation and apoptosis of fetal-derived trophoblasts, as well as promotes the inva-
sive capability of extravillous trophoblasts (EVT).Wehypothesize thatT3mayalsohave adirect impact onhumanmaternal-deriveddecidual cells,
which are known to exert paracrine regulation upon trophoblast behaviour and vascular development at the uteroplacental interface.
study design, size, duration: This laboratory-based study used human decidua from ﬁrst (8–11 weeks; n ¼ 18) and second
(12–16 weeks; n ¼ 12) trimester surgical terminations of apparently uncomplicated pregnancies.
participants/materials, setting, methods: Primary cultures of total decidual cells, and immunomagnetic bead-isolated
populations of stromal-enriched (CD10+) and stromal-depleted (CD102) cells, uterine natural killer cells (uNK cells; CD56+) and macro-
phages (CD14+) were assessed for thyroid hormone receptors and transporters by immunocytochemistry. Each cell population was treated
with T3 (0, 1, 10, 100 nM) and assessments were made of cell viability (MTT assay) and angiogenic growth factor and cytokine secretion (immu-
nomediated assay). The effect of decidual cell-conditioned media on EVT invasion through Matrigelw was evaluated.
mainresultsandtheroleofchance: Immunocytochemistryshowed theexpressionof thyroidhormone transporters (MCT8,
MCT10) and receptors (TRa1, TRb1) required for thyroid hormone-responsiveness in uNK cells andmacrophages from the ﬁrst trimester. The
viability of total decidual cells and the different cell isolates were unaffected by T3 so changes in cell numbers could not account for any observed
effects. In the ﬁrst trimester, T3decreasedVEGF-A secretionby total decidual cells (P, 0.05) and increased angiopoietin-2 secretion by stromal-
depleted cells (P, 0.05) but in the second trimester total decidual cells showed only increased angiogenin secretion (P, 0.05). In the ﬁrst tri-
mester, T3 reduced IL-10 secretion by total decidual cells (P, 0.05), and reduced granulocytemacrophage colony stimulating factor (P, 0.01),
IL-8 (P, 0.05), IL-10 (P, 0.01), IL-1b (P, 0.05) and monocyte chemotactic protein -1 (P, 0.001) secretion by macrophages, but increased
tumour necrosis factor-a secretion by stromal-depleted cells (P, 0.05) and increased IL-6 by uNK cells (P, 0.05). In contrast, in the second
& The Author 2014. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.
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trimesterT3 increased IL-10 secretion by total decidual cells (P, 0.01) but did not affect cytokine secretion by uNKcells andmacrophages.Con-
ditionedmedia fromﬁrst trimester T3-treated total decidual cells andmacrophages did not alter EVT invasion comparedwith untreated controls.
Thus, treatment of decidual cells with T3 resulted in changes in both angiogenic growth factor and cytokine secretion in a cell type-speciﬁc and
gestational age-dependent manner, with ﬁrst trimester decidual macrophages being the most responsive to T3 treatment, but these changes in
decidual cell secretome did not affect EVT invasion in vitro.
limitations, reasons for caution:Our results are based on in vitro ﬁndings andwe cannot be certain if a similar response occurs
in human pregnancy in vivo.
wider implications of thefindings:Optimalmaternal thyroid hormone concentrations could playa critical role inmaintaining a
balanced inﬂammatory response in early pregnancy to prevent fetal immune rejection and promote normal placental development through the
regulation of the secretion of critical cytokines and angiogenic growth factors by human decidual cells. Our data suggest that there is an ontogen-
ically determined regulatory ‘switch’ in T3 responsiveness between the ﬁrst and second trimesters, and support the notion that the timely and
early correction of maternal thyroid dysfunction is critical in inﬂuencing pregnancy outcomes.
study funding/competing interest(s): This study is funded by Wellbeing of Women (RG/1082/09 to S.Y.C., M.D.K.,
J.A.F., L.S.L., G.E.L.) andActionMedical Research – Henry Smith Charity (SP4335 toM.D.K., S.Y.C., L.S.L., J.A.F.). The authors have no conﬂicts
of interest to disclose.
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Introduction
Both maternal hypothyroidism and hyperthyroidism have been asso-
ciatedwith a rangeofmalplacentationdisorders such asmiscarriage, still-
birth, prematurity, pre-eclampsia and fetal growth restriction (Krassas
et al., 2010), leading to increased perinatal morbidity and mortality.
Even minor perturbations in maternal thyroid activity have been linked
to miscarriage (Negro et al., 2010), preterm delivery and placental
abruption (Casey et al., 2005). Increasing delay in achieving euthyroidism
in pregnancies complicated by maternal thyroid dysfunction has been
correlated with greater obstetric risks (Abalovich et al., 2002; LaFranchi
et al., 2005), suggesting that key thyroid-responsive events during
fetoplacental development are gestational age-dependent and may not
be corrected at a later stage of pregnancy. It is widely accepted that
inadequate transplacental passage of thyroid hormone (TH) from the
mother to the fetus in early pregnancy can affect fetal central nervous
systemdevelopment (deEscobaret al., 2008). In addition, it is postulated
thatmaternal THhasdirect effects uponplacental development itself and
may, thus, inﬂuence pregnancy outcome (Kilby et al., 2005).
Malplacentation disorders are characterized by shallow interstitial in-
vasion of fetal-derived trophoblast cells into maternal decidua and myo-
metrium, and impaired endovascular trophoblast invasion resulting in
incomplete maternal spiral artery remodelling. Spiral artery remodelling
is required for the establishment of high-ﬂow, low-resistance vessels for
effective maternal– fetal exchange (Khong et al., 1986). The differenti-
ation of cytotrophoblasts from a proliferative pluripotent phenotype
to extravillous trophoblasts (EVT) with an invasive phenotype starts in
the ﬁrst trimester and peaks in the early second trimester, with invasion
completed by 20 weeks of gestation. Trophoblast differentiation, inva-
sion, vascular remodelling and angiogenesis are tightly orchestrated by
a balance of autocrine and paracrine factors, which promote or inhibit
these processes. They involve the regulation of cytokine and growth
factor secretions in the crosstalk between fetal-derived cells and the
various maternal-derived decidual cell types (Bischof and Irminger-
Finger, 2005; Moffett and Loke, 2006). Decidual leukocytes (comprised
of 70% uterine natural killer (uNK) cells (Bulmer and Lash, 2005) and
20–25% macrophages (Nagamatsu and Schust, 2010)) are the major
sources of these secreted factors in decidua. In addition, this complex
cytokine network at the maternal– fetal interface is required to assert
immune privilege to prevent immune rejection of the fetus (Challis
et al., 2009). Thus, defective trophoblast invasion and aberrant expres-
sion of various cytokines and growth factors have been reported in mis-
carriage, preterm labour, pre-eclampsia and fetal growth restriction
(Moffett and Loke, 2006; Challis et al., 2009).
The main active ligand of TH is triiodothyronine (T3). Like the human
fetal-derived villous placenta and EVT (Kilby et al., 1998; Barber et al.,
2005), the human maternal decidua could be TH-responsive from
early pregnancy, as evidenced by the expression of the full complement
of proteins that are required tomediate THaction. There areTHplasma
membrane transporters monocarboxylate transporter (MCT) 8 and
MCT10 in decidual stroma (Chan et al., 2006; Loubiere et al., 2010)
which could facilitate cellular uptake of TH. There is generalized expres-
sion of the pre-receptor regulator deiodinase enzyme type 3 [D3; inac-
tivates thyroxine (T4) and T3] indicating the potential to modulate local
T3 concentrations (Huang et al., 2003).Decidual stroma, leukocytes and
endothelium express TH receptor isoforms (TRa1, TRb1), nuclear
transcription factors that can bind to T3, to regulate transcription of
TH-responsive genes (Barber et al., 2005). This indicates that decidual
cells can directly respond toTHat a timebefore andduring EVT invasion.
The increased risk ofmalplacentation disorderswith abnormalmater-
nal thyroid function tests during early pregnancy suggests a role for TH
in events of placentation during the ﬁrst and second trimesters.
Indeed, in fetal-derived ﬁrst trimester primary trophoblasts and chorio-
carcinoma cell lines, T3 has been shown to promote proliferation
(Matsuo et al., 1993), cell motility (Barber et al., 2005), invasion (Oki
et al., 2004; Vasilopoulou et al., 2013) and epidermal growth factor
(EGF) production (Matsuo et al., 1993) as well as to suppress apoptosis
(Laoag-Fernandez et al., 2004) in vitro. However, the actions of TH on
the maternal-derived decidual cell types are unknown.
We hypothesize that TH plays an important role in the regulation of
the cytokine and angiogenic growth factor milieu within the decidua,
which could impact upon placental development and, ultimately,
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pregnancyoutcome. In this study,weaimed to isolate theeffectsofT3on
speciﬁc decidual cell types in the ﬁrst and second trimesters.Wehave: (i)
conﬁrmed that different decidual cell populations demonstrate the sim-
ultaneous expression of proteins required to respond toT3, (ii) assessed
the effects of T3 upon decidual cell viability as well as angiogenic growth
factor and cytokine secretion by the sum of all decidual cells, stromal-
enriched and stromal-depleted cell populations, isolated uNK cells and
macrophages and (iii) investigated the paracrine impact on primary




Human samples were collected with informed written consent and with the
approval of the South Birmingham Research Ethics committee (Reference:
06/Q2707/12) and the Research and Development ofﬁce of the Walsall
Manor Hospitals NHS Trust (Project code: 2007013OG(W); approval
number: 11070745).
Sample collection
Placental and decidual samples were obtained from women undergoing
elective surgical termination of apparently uncomplicated pregnancies.
Samples were collected from 8–11 weeks of gestation (n ¼ 18; ﬁrst trimes-
ter) and 12–16weeks of gestation (n ¼ 12; second trimester) as determined
by ultrasound measurement of crown rump length or biparietal diameter
prior to pregnancy termination. The fetuses were not known to have abnor-
mal karyotypes and none of the pregnancies was complicated by thyroid
disorders.
Decidua cell isolation and culture
Following collection, placental and decidual tissues werewashed three times
with PBS to remove excess blood. Decidual tissue was ﬁnely minced and
added to 15 ml RPMI media (Invitrogen, Paisley, UK) containing 0.029%
(w/v) L-Glutamine (Life Sciences), 1000 units Penicillin and Streptomycin
(Life Sciences), 15 mg collagenase 1A (Sigma-Aldrich, Dorset, UK) and 585
units DNAse I (Sigma-Aldrich). The tissue was allowed to digest for 40 min
at room temperature on a rocking platform. The supernatant was sieved
through a 40 mm cell strainer and the cells (total decidual cells) were col-
lected by centrifugation. The digestion stepwas repeated with the remaining
tissue.
Total decidual cells were cultured in RPMI media supplemented with
L-Glutamine (Life Sciences), Penicillin and Streptomycin (Life Sciences) and
10% (v/v) charcoal-stripped fetal calf serum (which is devoid of thyroid
hormones and growth factors; FirstLink, Birmingham, UK) at a density of
1 × 105 cells/well of a 96-well plate) with 0, 1, 10 or 100 nM T3 for 24 h
in a 5% CO2 incubator at 378C.
For the puriﬁcationof different decidual cell types, total decidual cellswere
cultured in a 75 cm2ﬂask andallowed to adhereovernight. Stromal-enriched,
stromal-depleted, uNK cells and macrophages were puriﬁed by immu-
nomagnetic bead selection according to the manufacturer’s instructions
(Miltenyi Biotec, Surrey, UK). For the selection of stromal cells, all cells
were collected by trypsinization and incubatedwith amouseCD10 antibody
(1/100, Novocastra, Newcastle Upon Tyne, UK) for 30 min at 48C, washed
and incubated with anti-mouse IgG MicroBeads (Miltenyi Biotec). CD10
positive (stromal-enriched) and CD10 negative (stromal-depleted) cells
were obtained by magnetic separation. For the selection of uNK cells, the
cells in suspension were collected and incubated with a mouse CD56
antibody (1/100, Coulter, High Wycombe, UK) for 1 h at 48C, followed
by anti-mouse IgG MicroBeads (Miltenyi Biotec) and puriﬁed by magnetic
separation. For the selection of macrophages, the adherent cells were col-
lected by trypsinization, incubated with CD14 MicroBeads (Miltenyi
Figure1 Immunocytochemistryof puriﬁeddecidual cell types fromtheﬁrst trimester demonstrating immunoreactivity for thyroidhormone transporters
(monocarboxylate transporter (MCT) 8 and MCT10) and thyroid hormone receptors (TRa1 and TRb1). Top panel: uterine natural killer (uNK) cells
(CD56+), middle panel: macrophages (CD14+), bottom panel: stromal-enriched cells (CD10+). Each panel is of isolates fromone representative prep-
aration of cells. Negative controls were performed for each sample by replacing the primary antibody with non-immune serum.
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Biotec) and puriﬁed by magnetic separation. The CD14+ cell isolates were
comprised predominantly of macrophages but would also include mono-
cytes, which can later differentiate into CD14+ macrophages as well as
into CD142 dendritic cells. These CD14+ isolates were referred to as
macrophages in this paper. Cell purity was assessed by immunocytochem-
istry (Fig. 1, column 1) and was found to be over 95% for uNK cells and
over 90% for macrophages and stromal cells. All puriﬁed cell types were
counted and cultured in RPMI media as for the total decidual cells in
96-well plates (1 × 105 cells/well) with 0, 1, 10 or 100 nM T3 for 24 h in a
5% CO2 incubator at 378C. Cell-free conditioned media was collected and
stored at 2808C until required.
Immunocytochemistry
Following puriﬁcation, cells (0.5 × 105 cells per slide) were put onto micro-
scope slides and allowed to air-dry, ﬁxed in acetone and stored at 2208C.
For immunocytochemistry, sections were washed in PBS, incubated in 2%
BSA and 5% serum in PBS for 30 min to block non-speciﬁc binding and
then incubated in the primary antibody for 1 h at room temperature. The
antibodies usedwere:CD10 (1/100,Novocastra), CD56 (1/100,Novocas-
tra), CD14 (1/100, Leica Biosystems, Newcastle Upon Tyne, UK), MCT8
[ab4790, 1/800 (44)], MCT10 [Ab2198, 1/1000 (Vasilopoulou et al.,
2010)], TRa1 (1/200, Thermo Scientiﬁc, Rockford, IL, USA) and TRb1
(1/200, Thermo Scientiﬁc). The samples were further processed using an
anti-mouse or anti-rabbit avidin/biotin kit (Vectastain Elite, Vector Labora-
tories, Peterborough, UK) as per the manufacturer’s instructions. The stain-
ing was developed using a DAB Substrate kit (Vector Laboratories). The
samples were dehydrated in a series of graded ethanols, cleared in histoclear
and mounted. Negative controls were performed in parallel using non-
immune serum instead of the primary antibody. The TRa2 isoform, which
does not bind T3 (Koenig et al., 1989), and TRb2, which is not expressed
in human placenta (Kilby et al., 1998), were not evaluated. Immunocyto-
chemistry was performed in ﬁrst trimester decidual cell isolates but not per-
formed in second trimester isolates due to limited sample availability.
Cell viability assay
Cell viability was assessed 24 h after T3 treatment (0, 1, 10 or 100 nM) using
the methyltetrazoleum (MTT; Sigma-Aldrich) colourimetric assay as
described previously (Barber et al., 2005). Within each experiment, each
condition was assessed in four replicates and the absorbance values were
normalized to the values obtained with no T3 treatment (0 nM).
Assessment of angiogenic growth factor
and cytokine secretion
The secretion of angiogenic growth factors and cytokines in conditioned
media (collected 24 h after T3 treatment) was assessed using FAST Quant
human angiogenesis array and human cytokine II array according to theman-
ufacturer’s instructions (WhatmanGEHealthcare, Sanford,ME,USA) aspre-
viously described (Lash et al., 2010; Naruse et al., 2010). The angiogenesis
array included angiogenin, angiopoietin-2 (Ang-2), ﬁbroblast growth factor
basic (FGF-b), tissue inhibitor of metalloproteinase I (TIMP-1), intracellular
adhesion molecule 1 (ICAM-1), vascular endothelial growth factor-A
(VEGF-A), platelet-derived growth factor-BB (PDGF-BB) and keratinocyte
growth factor (KGF). The multi-cytokine panel tested for interleukin
(IL)-1b, IL-2, IL-4, IL-6, IL-8, IL-10, IL12p70, granulocyte macrophage
colony stimulating factor (GM-CSF), monocyte chemotactic protein-1
(MCP-1) and RANTES (regulated on activation normal T cell expressed
and secreted). Interferon (IFN)-g and tumour necrosis factor (TNF)-a
were quantiﬁed by ELISA (Duoset Development System, R&D Systems,
Abingdon, UK) according to the manufacturer’s instructions.
The concentrations of some factors in the conditioned media were below
or above the concentration range covered by the manufacturer’s standard
curve.Where one or more of the T3 treatments resulted in concentrations
outside the standard curve limits for a particular factor, the sample was
excluded from further analysis.Only factorswhere at least three cell prepara-
tions had a full dataset across the T3 concentrations were included. The ﬁnal
number of preparations included in the analysis for each cell population and
each secretory factorare shown in Supplementary data, Tables SI and SII. The
results were normalized to the values obtainedwith no T3 treatment (0 nM)
within each sample.
EVT isolation and invasion assay
Primary EVT cells were isolated from ﬁrst trimester human placentae, as
described previously (Lash et al., 2010) and cultured in cell culture inserts
(8 mm membrane pore size) coated with 10 ml of growth factor-reduced
Matrigelw matrix (BD Biosciences, Erembodegem, Belgium). Below the
inserts, conditionedmedia from cultured total decidual cells ormacrophages
(from 8 to 11 weeks of gestation samples) was added at a dilution of 1 in 3 in
normal culture medium (DMEM:F12). As previous studies have reported
peak EVT invasion with T3 treatment at 10 nM in vitro (Oki et al., 2004; Vasi-
lopoulou et al., 2013),weused conditionedmedia fromdecidual cells treated
with 10 nM T3 compared with that treated with 0 nM. Since T3 per se can
promote EVT invasion, as controls we also collected unconditioned media
(supplemented with 0 or 10 nM T3) from cell-free wells alongside each ex-
periment to account for the natural degradation of T3 and the decline in
T3 activity over the culture period and the freeze-thaw cycle. This enabled
us to distinguish between the effects of residual T3 in the media and the
effects of the decidual cell secretome. Cell invasion through Matrigelw was
assessed 60 h after culture by counting all the invaded cells visualized with
Mayer’s haematoxylin and eosin (H&E) staining. The invasion index was
determined and expressed as the ratio of invaded cells in the experimental
group relative to that in the control group (cell-free media, 0 nM T3).
Statistical analysis
Data were analysed using the Minitabw statistical software (version 15).
Repeated measures analysis of variance (ANOVA) was performed using
the general linear model. For the angiogenic growth factor and cytokine
data, each cell population in each trimester was considered separately with
T3 dose and factor-type as variables. For the EVT invasion assay, T3 dose
and cell-conditioning were the variables. Bonferroni pairwise multiple com-
parison (with control 0 nMT3) post hoc tests were used to assess differences
between individual groups. Residuals for all data sets passed the normality
test as determined using the Kolmogorov–Smirnov test. Statistical signiﬁ-
cance was taken as P, 0.05.
Results
Expression of TH transporters and receptors
in decidual cells
The simultaneous protein expression of the TH transporters,MCT8 and
MCT10, and TH receptors, TRa1 and TRb1, was demonstrated by im-
munocytochemistry in uNK cells (CD56+) andmacrophages (CD14+)
isolated from the ﬁrst trimester decidua (Fig. 1) conﬁrming previous
immunohistochemistry ﬁndings using parafﬁn-embedded intact human
decidual sections (Barber et al., 2005; Chan et al., 2006; Loubiere
et al., 2010). This indicates the capability of these isolated cells to
respond to TH. As shown in Fig. 1, uNK cells showed ubiquitous
TRa1 expression and many of the cells are also positive for TRb1,
MCT8 and MCT10. Isolated macrophages demonstrated widespread
immunoreactivity for both MCT8 and MCT10 as well as for both
TRa1 and TRb1. On the other hand, decidual stromal-enriched cells
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(CD10+) showed little immunopositivity for the TH receptors, even
thoughmanywere immunopositive forMCT8 andMCT10, as previously
demonstrated by immunohistochemistry in intact human decidual tissue
(Loubiere et al., 2010).
Effect of T3 on decidual cell viability as
measured by MTT assay
The viability of total decidual cells, stromal-enriched and stromal-
depleted cells, and isolates of uNK cells and macrophages from the
ﬁrst (Supplementary data, Figure S1) and second (data not shown) trime-
sters were unaffected by T3 treatment. Thus, any changes in angiogenic
growth factor or cytokine concentrations in conditioned media in these
subsequent experiments is not a consequence of altered cell numbers
but a true reﬂection of T3-responsive regulation of their secretion.
Effect of T3 on angiogenic growth factor
secretion by decidual cells
To investigate TH action in maternal decidua, we assessed the secretory
responses of decidual cells cultured in vitro to treatment by the active TH
ligand, T3. We ﬁrst examined angiogenic growth factor secretion.
In total decidual cells from ﬁrst trimester samples, T3 treatment
decreased VEGF-A secretion, with the greatest effect at a dose of
1 nM (40% reduction compared with no T3; P, 0.05; Fig. 2A). In the
second trimester, total decidual cells demonstrated increased angio-
genin secretion in response to T3 treatment with the greatest effect
observed with 1 nM T3 compared with no T3 (1.9-fold increase,
P, 0.05; Fig. 2B). However, the T3 effect on VEGF-A secretion was
lost. There were no signiﬁcant T3 effects on Ang-2, FGF-basic and
ICAM-1 secretion by ﬁrst and second trimester total decidual cells
(Supplementary data, Table SI).
We then assessed the effects on stromal-depleted cells, which com-
prise of the major growth factor secretors such as leukocytes, as well
as endothelium and epithelial cells. Treatment of ﬁrst trimester stromal-
depleted cells with 1 nM T3 resulted in a 2.7-fold increase in the secre-
tion of Ang-2 compared with no T3 (P, 0.05; Table I). In contrast,
ﬁrst trimester stromal-enriched cells did not demonstrate any signiﬁcant
T3-responsive effects.
Isolated uNK cells from the ﬁrst trimester showed no signiﬁcant
T3-responsive effects (Fig. 3A), suggesting that other cell types are re-
sponsible for the increased Ang-2 secretion observed in the stromal-
depleted cell population. These may include secretion by macrophages,
where Ang-2 concentrations were above the upper limit of the standard
curve. Unlike the ﬁrst trimester, second trimester uNK cells demon-
strated trends of dose-dependent increases in the secretion of angio-
genin, Ang-2, TIMP-1, ICAM-1 and VEGF-A, which just failed to reach
statistical signiﬁcance (overall effect of T3: P ¼ 0.077; Fig. 3B).
Of the angiogenic growth factors secreted by macrophages which
were within the detection thresholds (Angiogenin, VEGF-A, FGF-basic),
none demonstrated statistically signiﬁcant changes in response to T3
treatment (Supplementary data, Table SI).
PDGF-BB was below the detection limit in all decidual samples and
KGF was only just detectable in a few samples. TIMP1 concentrations
by total decidual cells and macrophages were above the limit of the
standard curve.
Effect of T3 on cytokine secretion by decidual
cells
There were substantial changes in the secretion of cytokines by decidual
cells following T3 treatment in vitro, predominantly in the ﬁrst trimester.
In ﬁrst trimester total decidual cells, T3 treatment signiﬁcantly
decreased IL-10 secretion with the most prominent effect observed
when cells were treated with 1 or 100 nM T3 (30% reduction;
P, 0.05 for both; Fig. 4A). In contrast, IL-10 secretion by second tri-
mester total decidual cells was signiﬁcantly increased in response to
T3, with the highest effect occurring at 1 nM (70% increase; P, 0.05;
Fig. 4B). In both ﬁrst and second trimester total decidual cells, T3 treat-
ment did not result in any signiﬁcant differences in IL-8, GMCSF, IL-1b,
MCP-1, IFN-g and TNF-a secretion (Supplementary data, Table SII).
In stromal-depleted cells from the ﬁrst trimester (Table II), the secre-
tion of MCP-1 was down-regulated by T3, particularly at 10 nM which
caused a 30% reduction (P, 0.05), but TNF-a secretion was up-
Figure 2 Effect of triiodothyronine (T3) on angiogenin and VEGF-A (vascular endothelial growth factor-A) secretion by total decidual cells after 24 h of
treatment with 0, 1, 10 or 100 nMT3. (A) Isolated from ﬁrst trimester samples, (B) isolated from second trimester samples.Within each experiment, the
angiogenic growth factor concentration was compared with that after no T3 treatment (0 nM), which was given an arbitrary value of 1. Bars represent
mean + SEM. Statistical signiﬁcance *P, 0.05.
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regulated by 30% at 1 and 10 nM T3 compared with no T3 (P, 0.05 for
both). No T3-responsive effects were observed in stromal-enriched cells.
In the ﬁrst trimester, treatment of uNKcells onlywith the highest dose
of T3 (100 nM) resulted in a statistically signiﬁcant increase in IL-6 secre-
tion (1.8-fold compared with no T3; P, 0.05; Fig. 5A). However, T3
treatment hadno signiﬁcant effects on IL-6 secretionby second trimester
uNK cells (Fig. 5B). The secretion of other quantiﬁable cytokines by uNK
cells did not demonstrate any signiﬁcant changes in response to T3 treat-
ment (Supplementary data, Table SII).
The cells that were most affected by T3 treatment were the ﬁrst tri-
mester decidualmacrophages,where the secretion ofmultiple cytokines
was decreased in response to T3 treatment (Fig. 6A), with the exception
of IFN-g and TNF-awhich both showed no signiﬁcant changes (Supple-
mentary data, Table SII). The secretion of IL-8 was reduced by 30% fol-
lowing treatmentwith 1or 10 nMT3 comparedwith noT3 (P, 0.05 for
both) and the secretion of GM-CSF was decreased by 35% with 10 or
100 nM T3 compared with no T3 (P, 0.01 for both). IL-10 secretion
was also reduced with T3 treatment with the most pronounced effect
when the cells were treated with 100 nM T3 (50% reduction compared
with no T3; P, 0.01), suggesting that this effect may account for the
overall IL-10 reduction observed in total decidual cells. Furthermore,
IL-1b secretion was reduced by 30% at 1 nM T3 (P, 0.05), 40% at
10 nM T3 (P, 0.01) and 35% at 100 nM T3 (P, 0.05). Finally,
MCP-1 secretion wasmost notably affected by T3 treatment with a sub-
stantial 50% reduction observed at all T3 doses (P, 0.001). In contrast,
macrophages from second trimester decidua demonstrated no signiﬁ-
cant changes in response to T3 treatment (Fig. 6B).
In all decidual samples, IL12p70 and IL-4 were below the detection
limit whilst IL-2 was only detectable at low concentrations in a handful
of samples. RANTES and IL-6 concentrations were above the upper
limit of the standard curve in conditioned media from total decidual
cells and macrophages.
Effect of conditioned media from T3-treated
decidual cells on EVT invasion
Given our observations that T3 treatment affects angiogenic growth
factors and cytokine secretion by decidual cells, we next investigated
whether the changes in the decidual cell secretome could regulate EVT
invasion in a paracrinemanner. Since the effects of T3 weremore prom-
inent in ﬁrst trimester cells and particularly so in ﬁrst trimester macro-
phages, we investigated this using conditioned media from ﬁrst
trimester total decidual cells and ﬁrst trimester decidual macrophages.
When we compared the invasiveness of ﬁrst trimester EVT cells
treatedwith conditionedmedia obtained fromT3-treated total decidual
cells (Fig. 7A) or from T3-treated macrophages (Fig. 7B) with their
respective untreated cellular controls, we found no signiﬁcant differ-
ences. Since T3 is known to have a direct pro-invasive effect upon
EVT, it was important to determine if the initial T3 added to media
could still affect EVT invasion directly, and to disentangle this effect
from that of the decidual secretome. Results from cell-free media
showed thatT3 added towells in initial experiments no longer had a stat-
istically signiﬁcant effect in subsequent EVT invasion experiments, al-
though a trend towards increased invasive capacity was still seen. A
similar decline in T3 effectiveness due to its natural degradation in decid-
ual cell-conditionedmedia from parallel experiments is assumed. In fact,
it is likely that there would be even less residual T3 in the decidual cell-
conditioned media due to T3 inactivation by cellular D3 activity, which
is not present in cell-free wells. Thus, we conclude that the effect of de-
cidual cell-conditioned media on EVT invasion is largely independent of
the initial T3 added.
Whenwecompared the invasivenessof EVT treatedwith conditioned
media from total decidual cells with media collected from cell-freewells,
there appeared to be an overall trend towards increased invasion al-
though this did not reach statistical signiﬁcance (P ¼ 0.3; Fig. 7A). The
conditioned media from decidual macrophages also did not alter EVT
invasiveness when compared with media collected from cell-free wells
(P ¼ 0.2; Fig. 7B). These observations indicate that the summation of
secretome effects from either total decidual cells or macrophages did
not affect EVT invasion in our experimental model.
Discussion
These results demonstrate that speciﬁc maternal-derived decidual cells
show a coordinated expression of the proteins required for TH action
and are T3-responsive in early human gestation. The effects of T3 on
angiogenic growth factor and cytokine secretion in vitro are cell type-
speciﬁc and gestational age-dependent. Opposing effects of T3
between the ﬁrst and second trimester on the secretion of IL-10, one
of the central regulatory cytokines in human pregnancy (Thaxton and
Sharma, 2010; Brogin et al., 2012), indicate an ontogenically-determined
regulatory ‘switch’ in T3 responsiveness within human decidua. Further-
more, ﬁrst trimester macrophages demonstrated the most marked T3
responsiveness indicated by the down-regulation of a range of cytokines,
a response that was attenuated in second trimester macrophages. Simi-
larly, in ﬁrst trimester uNK cells, T3 invoked different proﬁles of angio-
genic growth factor and cytokine secretion compared with second
trimester uNKcells.Overall, T3 appears to participate in the timely regu-
lation of speciﬁc paracrine factors in the human decidua, which could fa-
cilitate placentation events appropriate for the stage of gestation.
........................................................................................
Table I Effect of T3 on selected angiogenic growth
factor secretion by first trimester stromal-depleted
(CD102) and stromal-enriched (CD101) cells
T3 (nM) Angiogenin Ang-2 VEGF-A
CD102 N ¼ 5 N ¼ 4 N ¼ 5
0 1 1 1
1 1.1+0.2 2.7+1.3* 1.8+0.8
10 1.1+0.3 1.2+0.1 1.8+0.8
100 1.2+0.4 0.9+0.1 1.6+0.7





Data are normalized to 0 nMwithin each experiment and presented as mean+ SEM.
Ang-2 concentrations in CD10+ cells and ﬁbroblast growth factor basic (FGF-basic),
tissue inhibitor of metalloproteinase I (TIMP-1), intracellular adhesion molecule 1
(ICAM-1) concentrations in both CD102 and CD10+ cells were above the
manufacturer’s standard curve limit. Platelet-derived growth factor-BB (PDGF-BB)
was below the detection limit in all samples and keratinocyte growth factor (KGF) was
only detectable in two or less samples per experimental set.
Ang-2, Angiopoietin-2; VEGF-A, vascular endothelial growth factor-A.
*P,0.05 compared with no T3 treatment (0 nM).
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Figure3 Effect of triiodothyronine (T3) on angiogenic growth factor secretion by uterine natural killer (uNK) cells after 24 h of treatmentwith 0, 1, 10 or
100 nM T3. (A) Isolated from ﬁrst trimester samples, (B) isolated from second trimester samples.Within each experiment, the angiogenic growth factor
concentration was comparedwith that after no T3 treatment (0 nM), which was given an arbitrary value of 1. Bars represent mean + SEM. FGF, ﬁbroblast
growth factor; TIMP-1, tissue inhibitor of metalloproteinase I; ICAM-1, intracellular adhesion molecule 1; VEGF-A, vascular endothelial growth factor-A.
Figure 4 Effect of triiodothyronine (T3) on interleukin (IL)-10 secretion by total decidual cells after 24 h of treatment with 0, 1, 10 or 100 nM T3. (A)
Isolated fromﬁrst trimester samples, (B) isolated fromsecond trimester samples.Withineachexperiment, the IL-10 concentrationwas comparedwith that
after no T3 treatment (0 nM), which was given an arbitrary value of 1. Bars represent mean + SEM. Statistical signiﬁcance *P, 0.05.
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The stromal-enriched cells which lacked TR expression showed no
change in angiogenic growth factor or cytokine secretion with T3 treat-
ment. However, their expression of MCT8 and MCT10 could facilitate
TH uptake and these cells could play a role in regulating local tissue
TH concentrations through deiodinasemetabolism (Huang et al., 2003).
Circulating total T3 concentrations in adults are in the region of 0.1–
1 nM but the local intracellular concentrations of T3 in decidua are not
known and may be different as a result of local deiodinase type 2 (con-
verts T4 to T3) and type 3 (inactivates T3) activities. Almost all of the
statistically signiﬁcant decidual cell responses in our study occurred at a
physiological concentration of 1 nM T3 treatment in vitro, with many
also occurring at higher T3 concentrations.
Angiogenic growth factors are critical to the development of bothma-
ternal and fetal vasculature at the uteroplacental interface. Our data
suggest that T3 affects the timely decidual secretion of three key angio-
genic growth factors implicated in humanplacentation. In the ﬁrst trimes-
ter, VEGF-A, which promotes maternal and fetoplacental angiogenesis
(Wulff et al., 2003) as well as EVT motility (Lash et al., 1999), is down-
regulated by T3 in total decidual cells. This is appropriate as it is at a
time prior to the peak of EVT invasion when invasion needs to be
tightly controlled. In contrast, Ang-2, which destabilizes vasculature
and mediates some of the initial stages of spiral artery remodelling
(Robson et al., 2012), is appropriately up-regulated in stromal-depleted
cells in preparation for the next phase of placentation. In the second tri-
mester, the secretion of angiogenin (a potent inducer of angiogenesis
whose placental expression increases with gestation (Rajashekhar
et al., 2002)) by total decidual cells is suitably up-regulated by T3.
In normal pregnancy, the balance of the anti-inﬂammatory versus
pro-inﬂammatory milieu changes in favour of immunosuppression to
prevent immune rejection of the fetal allograft and promote normal pla-
cental cytoarchitectural development (Moffett and Loke, 2006; Challis
et al., 2009). Our data support a role for T3 in the regulation of this
balance at the uteroplacental interface.
Central to this T3-modulated response is the regulation of decidual
IL-10 secretion. The anti-inﬂammatory response of pregnancy is domi-
nated by a signiﬁcant rise in IL-10 during the ﬁrst trimester. A high level
of IL-10 is sustained across the rest of pregnancy before its decline
prior to the onset of labour (Thaxton and Sharma, 2010). In addition,
IL-10 promotes EVT differentiation (Moreau et al., 1999), inhibits EVT
invasion (Pang et al., 2008) and indirectly stimulates angiogenesis
(Thaxton and Sharma, 2010). Our results indicate that T3 down-
regulates IL-10 secretion by ﬁrst trimester total decidual cells andmacro-
phages. This is in contrast to the up-regulation of IL-10 by second
........................................................................................
Table II Effect of T3 on selected cytokine secretion by
first trimester stromal-depleted (CD102) and
stromal-enriched (CD101) cells
T3 (nM) IL-10 MCP-1 TNF-a
CD102 N ¼ 6 N ¼ 6 N ¼ 6
0 1 1 1
1 0.8+0.1 0.8+0.1 1.3+0.2*
10 0.7+0.1 0.7+0.1* 1.3+0.2*
100 0.7+0.1 0.8+0.1 1.3+0.2
CD10+ N ¼ 5 N ¼ 6 N ¼ 7
0 1 1 1
1 1.3+0.2 0.9+0.1 0.9+0.1
10 1.1+0.3 1.0+0.1 0.9+0.1
100 1.2+0.2 1.2+0.1 0.7+0.1
Data are normalized to 0 nMwithin each experiment and presented as mean+ SEM.
There were no signiﬁcant changes in IL-8, GM-CSF (granulocyte macrophage colony
stimulating factor), IL-1b and interferon-g in response to T3 treatment (data not
shown). RANTES (regulated on activation normal T cell expressed and secreted) and
interleukin (IL)-6 concentrations in both CD102 and CD10+ cells were above the
manufacturer’s standard curve limit. IL12p70 and IL-4 were below the detection limit
in all samples and IL-2wasonly detectable in twoor less samples per experimental set.
IL, interleukin; MCP, monocyte chemotactic protein; TNF, tumour necrosis factor.
*P, 0.05 compared with no T3 treatment (0 nM).
Figure5 Effect of triiodothyronine (T3) on interleukin (IL)-6 secretion by uterine natural killer (uNK) cells after 24 hof treatmentwith 0, 1, 10or 100 nM
T3. (A) Isolated from ﬁrst trimester samples, (B) isolated from second trimester samples.Within each experiment, the IL-6 concentration was compared
with that after no T3 treatment (0 nM), which was given an arbitrary value of 1. Bars represent mean + SEM. Statistical signiﬁcance *P, 0.05.
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trimester total decidual cells, an effectmediated through cells other than
uNKcells andmacrophages. T3 appears tomodulate and prevent exces-
sive IL-10 production initially, perhaps to control EVT differentiation, but
at the peak of EVT invasion and spiral artery remodelling in the early
second trimester T3 increases IL-10 in the decidual secretome. T3
may play an important role in maintaining a high level of IL-10 from the
second trimester of pregnancy, which is a feature associated with a
reduced risk of pre-eclampsia, fetal growth restriction and preterm
birth (Thaxton and Sharma, 2010; Brogin et al., 2012). It is tempting to
speculate that maternal thyroid dysfunction could affect pregnancy
outcome through the inappropriate and untimely modulation of this
key cytokine, IL-10, at the maternal– fetal interface.
T3 also appears to increase the decidual secretion of the
pro-inﬂammatory cytokine, TNF-a by ﬁrst trimester stromal-depleted
cells, which could indirectly promote decidual macrophage recruitment
(Lockwood et al., 2006; Renaud et al., 2009).
Amongst the decidual cell types examined, ﬁrst trimester macro-
phages showed the most widespread expression of TH transporters
and receptors and appeared to be the most T3-responsive. However,
these decidual macrophages became completely unresponsive to T3 in
the second trimester, suggesting the existence of a potent ontogenically
determined ‘switch’ in T3 responsiveness within this cell type. In the ﬁrst
trimester, T3 reduced the secretion of the macrophage activator,
GM-CSF [which is increased in pre-eclamptic decidua (Huang et al.,
2010)], and the macrophage chemoattractant, MCP-1. This suggests
that T3 could be participating in the autoregulation of macrophage
numbers and responses within the decidua to prevent excessive macro-
phage recruitment which could promote EVT apoptosis (Wu et al.,
2012) and impair endovascular EVT invasion (Lockwood et al., 2006)
leading to complications like pre-eclampsia and fetal growth restriction.
In addition, the pro-inﬂammatory cytokines, IL-8 and IL-1b, and the anti-
inﬂammatory IL-10 were similarly down-regulated. The ability of a single
factor to reduce the secretion of amixture of anti- and pro-inﬂammatory
cytokines simultaneously by the same cell type at the uteroplacental
interface is not unusual and has previously been reported for other
factors such as thrombopoietin (Segerer et al., 2013).
T3 has previously been shown to regulate angiogenic growth factor
and cytokine secretion during bone marrow-derived dendritic cell mat-
uration (Mascanfroni et al., 2008) and in human hepatocarcinoma cells
(Bockhorn et al., 2007). The mechanisms underlying the T3 regulation
Figure6 Effect of triiodothyronine (T3) on cytokine secretion by decidual macrophages after 24 h of treatment with 0, 1, 10 or 100 nMT3. (A) Isolated
fromﬁrst trimester samples, (B) isolated fromsecond trimester samples.Within eachexperiment, the cytokine concentrationwas comparedwith that after
no T3 treatment (0 nM), which was given an arbitrary value of 1. Bars represent mean + SEM. Statistical signiﬁcance *P, 0.05, **P, 0.01, ***P, 0.001.
IL, interleukin; GM-CSF, granulocyte macrophage colony stimulating factor; MCP-1, monocyte chemotactic protein-1.
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of decidual cell secretome remain to be determined. One possibility is
that T3 regulates the transcription of these genes, either directly or indir-
ectly, which could be substantiated by quantiﬁcation of gene expression.
For instance, in rat liveraT3-inducedhypermetabolic state increasesoxi-
dative stress and enhances the activity of redox sensitive transcription
factors, leading to increased transcription of antioxidant cytokines such
as TNFa and IL-10 (Fernandez et al., 2006).
Themechanism thatunderlies theobservedontogenically determined
‘switch’ in T3 responsiveness in different subpopulations of decidual cells
is alsonot known. It is possible thatquantitativechanges in theexpression
of TH transporters, receptors or deiodinase enzymes between the ﬁrst
and second trimesters affect the ability of the cells to take-up and
respond to T3. In addition, the apparent summation of T3 effects
observed in stromal-enriched and stromal-depleted cells does not
always correspond with the T3 response seen in total decidual cell cul-
tures (e.g. VEGF-A, IL-10 secretion) suggesting that interactions across
the two cell populations play a role in regulating the secretion of these
factors.
Amongst the secreted factors found to be regulated by T3 in decidua,
TNF-a (Otun et al., 2011), GM-CSF (Wu et al., 2012) and IL-10 (Pang
et al., 2008) have all been reported to attenuate EVT invasion. IL-1b
and VEGF-A promote EVT motility (Lash et al., 1999; Prutsch et al.,
2012) and IL-8 promotes EVT invasion (De Oliveira et al., 2010) whilst
IL-6 has no effect (Champion et al., 2012). However, we did not
observe the expected increase in EVT invasion in vitro as a result of
T3-induced suppression of IL-10 in ﬁrst trimester total decidual cell secre-
tome, suggesting that there are other factors counteracting the lack of
IL-10. Similarly, the T3-induced changes in ﬁrst trimester macrophage
secretome included the suppression of both pro-invasive and inhibitory
factors such that the overall summation of secretome changes resulted
in no effect on EVT invasion in our experimental model. None the less
this result does not diminish the potential importance of the T3-induced
changes in decidual secretome upon other placentation events occurring
in vivo, such as immune cell recruitment and function, angiogenesis and
vascular remodelling, which we have not yet investigated.
In conclusion, optimal maternal and uteroplacental TH concentra-
tions could play a critical role in maintaining a balanced inﬂammatory re-
sponse in pregnancy to prevent fetal immune rejection and promote
normal placental development through the regulation of the secretion
of critical cytokines and angiogenic growth factors by human decidual
cells in a cell type-speciﬁc and gestational age-dependent manner. The
nature of the ontogenically determined regulatory ‘switch’ in T3 respon-
siveness between the ﬁrst and second trimester remains to be discov-
ered. Our data support the notion that timely and early correction of
maternal thyroid dysfunction by the ﬁrst trimester of pregnancy may
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Figure 7 Effect of conditioned media from triiodothyronine
(T3)-treatedﬁrst trimester total decidual cells (A) orT3-treated ﬁrst tri-
mester macrophages (B) on invasion by ﬁrst trimester extravillous tro-
phoblasts (EVT). Unconditionedmedia (supplementedwith 0 or 10 nM
T3) from cell-free wells alongside each experiment were used as con-
trols (Cell-free). Within each experiment, each condition was per-
formed in duplicate and the results normalized to the mean value for
the control (0 nM T3, cell-free) which was given an arbitrary value of
1. Bars represent mean of nine experiments + SEM.
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